the effectiveness of Rocaltrol on treatment of albuminuria in pateint with diabetic nephropathy.

investigation of the effectiveness of combination of losartan with Rocaltrol on treatment of albuminuria in patient with diabetic nephropathy; a clinical trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015110624903N1

Enrollment

132

Registered

2015-11-29

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy. Non-insulin-dependent diabetes mellitus with renal complications

Interventions

Intervention 1: case group : Patients with diabetic nephropathy without vitamin D deficiency (66 patients) enroll to the study considering inclusion and exclusion criteria and they will be investigate

Ca, P, HbA1C, Urine Albumin and Creatinine, also the ACR ( Urine Albumin to creatinine ratio) will be calculated. They receive combination therapy with Losartan 25 mg/PO twice per day and Rocaltrol on

Ca, P, HbA1C, Urine Albumin and Creatinine, also the ACR ( Urine Albumin to creatinine ratio) will be calculated. They receive Losartan 25 mg/PO twice per day for 3 months. Afterwards, at the end of t

Treatment - Drugs

case group : Patients with diabetic nephropathy without vitamin D deficiency (66 patients) enroll to the study considering inclusion and exclusion criteria and they will be investigate regarding lipi

Control group: Patients with diabetic nephropathy without vitamin D deficiency (66 patients) enroll to the study considering inclusion and exclusion criteria and they will be investigate regarding li

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: aged between 40-70 years; diabetes mellitus type 2 that at least 3 months past diagnosis; Albuminuria is (urinary albumin >30 mg/24 hours); Signing Informed consent form; ca 5.5 mg per deciliter or creatinine rising more than 30% after administration of Losartan; administration of vitamin D agents; acute infectious disease; acute heart failure; cancer; pregnancy; Urinary protein more than 8 gr/24 hours; vitamin D deficiency.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HbA1C. Timepoint: 3 month later. Method of measurement: labratory study.;Albumin to createnin ratio. Timepoint: 3 month later. Method of measurement: labratory study.	—

Secondary

Measure	Time frame
Ca. Timepoint: 3 month later. Method of measurement: Labratory Study.;P. Timepoint: 3 month later. Method of measurement: Labratory Study.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Hadidi

Arak University of Medical sceinces

dr_hadidy@yahoo.com+98 86 3417 3601

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026